Małgorzata Benedyk-Machaczka

Dr. Małgorzata Benedyk-Machaczka


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2015 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
MBMałgorzata Benedyk-Machaczka
Małgorzata Benedyk-Machaczka
PMPiotr Mateusz Mydel
Piotr Mateusz Mydel
NDNicolas Delaleu
Nicolas Delaleu
KPKarolina Płaza
Karolina Płaza
KGKatarzyna Gawron
Katarzyna Gawron
JPJan Potempa
Jan Potempa
Aspiration pneumonia is a life-threatening infectious disease often caused by oral anaerobic and periodontal pathogens such as Porphyromonas gingivalis. This organism produces proteolytic enzymes, known as gingipains, which manipulate innate immune responses and promote chronic inflammation. Here, we challenged mice with P. gingivalis W83 and examined the role of gingipains in bronchopneumonia, lung abscess formation, and inflammatory responses. Although gingipains were not required for P. gingivalis colonization and survival in the lungs, they were essential for manifestation of clinical symptoms and infection-related mortality. Pathologies caused by wild-type (WT) P. gingivalis W83, including hemorrhage, necrosis, and neutrophil infiltration, were absent from lungs infected with gingipain-null isogenic strains or WT bacteria preincubated with gingipain-specific inhibitors. Damage to lung tissue correlated with systemic inflammatory responses, as manifested by elevated levels of TNF, IL-6, IL-17, and C-reactive protein. These effects were unequivocally dependent on gingipain activity. Gingipain activity was also implicated in the observed increase in IL-17 in lung tissues. Furthermore, gingipains increased platelet counts in the blood and activated platelets in the lungs. Arginine-specific gingipains made a greater contribution to P. gingivalis-related morbidity and mortality than lysine-specific gingipains. Thus, inhibition of gingipain may be a useful adjunct treatment for P. gingivalis-mediated aspiration pneumonia.

Verified
Journal Article
Open access
PDF file
AAArdita Aliko
Ardita Aliko
MKMarta Kamińska
Marta Kamińska
KFKatherine Falkowski
Katherine Falkowski
EBEwa Bielecka
Ewa Bielecka
MBMałgorzata Benedyk-Machaczka
Małgorzata Benedyk-Machaczka
PMPiotr Mateusz Mydel
Piotr Mateusz Mydel
Citrullination, a posttranslational modification, is catalyzed by peptidylarginine deiminases (PADs), a unique family of enzymes that converts peptidyl-arginine to peptidyl-citrulline. Overexpression and/or increased PAD activity is observed in rheumatoid arthritis (RA), Alzheimer’s disease, multiple sclerosis, and cancer. Moreover, bacterial PADs, such as Porphyromonas gingivalis PAD (PPAD), may have a role in the pathogenesis of RA, indicating PADs as promising therapeutic targets. Herein, six novel compounds were examined as potential inhibitors of human PAD4 and PPAD, and compared to an irreversible PAD inhibitor, Cl-amidine. Four of the tested compounds (compounds 2, 3, 4, and 6) exhibited a micromolar-range inhibition potency against PAD4 and no effect against PPAD in the in vitro assays. Compound 4 was able to inhibit the PAD4-induced citrullination of H3 histone with higher efficiency than Cl-amidine. In conclusion, compound 4 was highly effective and presents a promising direction in the search for novel RA treatment strategies.

20 August 2019 in Molecular Oral Microbiology
Verified
Journal Article
Closed access
PDF file
MBMałgorzata Benedyk-Machaczka
Małgorzata Benedyk-Machaczka
AMAgata Marczyk
Agata Marczyk
BCBarbara Chruścicka
Barbara Chruścicka

1 June 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SMStanisław Malicki
Stanisław Malicki
BPBarbara Pucelik
Barbara Pucelik
EZEdyta Zyla
Edyta Zyla
MBMałgorzata Benedyk-Machaczka
Małgorzata Benedyk-Machaczka
WGWojciech Gałan
Wojciech Gałan
GDGrzegorz Dubin
Grzegorz Dubin
Immune checkpoint targeting immunotherapy has revolutionized the treatment of certain cancers in the recent years. Determination of the status of immune checkpoint expression in particular cancers may assist decision making. Here, we describe the development of a single-stranded aptamer-based molecular probe specifically recognizing human PD-L1. Target engaging aptamers are selected by iterative enrichment from a random ssDNA pool and the binding is characterized biochemically. Specificity and dose dependence is demonstrated in vitro in the cell culture using human kidney tumor cells (786-0), human melanoma cells (WM115 and WM266.4) and human glioblastoma LN18 cancer cells. The utility of the probe in vivo is demonstrated using two mouse tumor models, where we show that the probe exhibits excellent potential in imaging. We postulate that further development of the probe may allow universal imaging of different types of tumors depending on their PD-L1 status, which may find utility in cancer diagnosis.

21 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
VNValeria Napolitano
Valeria Napolitano
ADAgnieszka Dąbrowska
Agnieszka Dąbrowska
KSKenji Schorpp
Kenji Schorpp
AMAndré Mourão
André Mourão
EBEmilia Barreto-Duran
Emilia Barreto-Duran
KPKrzysztof Pyrc
Krzysztof Pyrc
S ummary: The COVID-19 pandemic caused by SARS-CoV-2 has been socially and economically devastating. Despite an unprecedented research effort, effective therapeutics are still missing to limit severe disease and mortality. Using high-throughput screening, we identified acriflavine as a potent papain-like protease (PL pro ) inhibitor. NMR titrations and a co-crystal structure confirm that acriflavine blocks the PL pro catalytic pocket in an unexpected binding mode. We show that the drug inhibits viral replication at nanomolar concentration in cellular models, in vivo in mice and ex vivo in human airway epithelia, with broad range activity against SARS-CoV-2 and other betacoronaviruses. Considering that acriflavine is an inexpensive drug approved in some countries, it may be immediately tested in clinical trials and play an important role during the current pandemic and future outbreaks.

5 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMałgorzata Benedyk-Machaczka
Małgorzata Benedyk-Machaczka
PMPiotr Mydel
Piotr Mydel
Karsten MäderKarsten Mäder
Karsten Mäder
MKMarta Kaminska
Marta Kaminska
NTNadine Taudte
Nadine Taudte
MBMirko Buchholz
Mirko Buchholz
Adjunctive treatment of periodontitis lacks solutions allowing enough time for wound healing in the periodontal pockets by avoiding a fast re-colonization. Such a solution might be an antibiotic containing formulation with a controlled release over weeks. Here, a recently described minocycline containing approach is qualified for further clinical development by focusing on proof-of-concept, systemic burden, resistance development and degradation studies. Animal studies were done in two different (mouse-chamber, rat Porphyromonas gingivalis challenging) models, including effects on inflammation markers, bone loss and bone structure. Also, serum concentrations of minocycline after local application were determined by HPLC-MS/MS. The resistance status of bacterial clinical isolates against minocycline was investigated and the degradation of the formulation was characterized by laser scanning- and scanning electron microscopy. Animal studies clearly demonstrated the applicability of the new formulation in the investigated models. Inflammation markers decreased dosage dependent and reduced bone loss compared to non-treated group was observed. Thereby, the systemic burden of the antibiotic was neglectable. Minocycline is still effective against oral pathogens; resistance development was not seen. The biodegradable thread was first swollen and subsequently degraded over weeks. The results support the continued clinical development of this new formulation. A phase I clinical trial is planned to further evaluate its safety and efficacy.